European Slowdown Taking Toll on Big Pharma
The Paragon Report Provides Equity Research on Pfizer & AstraZeneca

NEW YORK, NY -- (Marketwire) -- 03/01/12 -- Major Pharmaceutical firms have performed admirably in the first couple months of the year. In Europe, firms are putting more emphasis on cutting costs and increasing exposure to emerging markets. Meanwhile U.S. manufacturers are benefiting from an improving domestic economy. The iShares Dow Jones U.S. Pharmaceuticals Index Fund is up roughly 3.4 percent over the last month -- outperforming the Dow Jones Industrial Average. The Paragon Report examines the outlook for companies in the Drug Manufacturers - Major Industry and provides equity research on Pfizer, Inc. (NYSE: PFE) and AstraZeneca Plc (NYSE: AZN) (LSE: AZN). Access to the full company reports can be found at:

www.paragonreport.com/PFE

www.paragonreport.com/AZN

The Eurozone debt crisis is taking a toll on Big Pharma's European profits. A recent review in The New York Times says that the profits, and hence the share price, of 'Big Pharma' is set to remain stagnant in Europe until at least 2014. Budget cuts mean that many European governments are not willing to pay as much for pills, Stephanie Novak of the New York Times reports.

European pharmaceutical companies have been successful in emerging markets in the last five years, helping to offset troubles at home, Novak reports. Meanwhile, American companies do not rely as much on overseas revenue because of their large domestic market.

The Paragon Report provides investors with an excellent first step in their due diligence by providing daily trading ideas, and consolidating the public information available on them. For more investment research on the Drug Manufacturers - Major Industry register with us free at www.paragonreport.com and get exclusive access to our numerous stock reports and industry newsletters.

Pfizer Inc., a biopharmaceutical company, offers prescription medicines for humans and animals worldwide. Last month Pfizer announced the acquisition of privately-held Alacer Corp., the maker and distributor of Emergen-C products, the largest selling branded Vitamin C line in the United States. Alacer Corp produces almost 500 million packets of the popular Emergen-C supplement annually, and its products are sold in health food stores, supermarkets, drug stores, mass merchandisers and club stores nationwide.

UK-based AstraZeneca PLC discovers, develops, and commercializes prescription medicines for cardiovascular, gastrointestinal, infection, neuroscience, oncology, and respiratory and inflammation diseases worldwide. The company recently reported that Caprelsa has been approved in the EU for the treatment of aggressive and symptomatic medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease.

The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at http://www.paragonreport.com/disclaimer

Add to Digg Bookmark with del.icio.us Add to Newsvine

Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here

Portions of this content may be copy written by Fresh Brewed Media, Investors Observer, and/or O2 Media LLC. SmartReadMX and other related related technologies used to produce content for this service are covered by US Patents numbers 7,865,496, 7,856,390, and 7,716,116.